Genomic tools in acute myeloid leukemia: From the bench to the bedside

Cancer

Volumn 120, Issue 8, 2014, Pages 1134-1144

  White, Brian S ^a   DiPersio, John F ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA   (United States)

Author keywords

acute myeloid leukemia; epigenomics; gene expression profiling; genomics; high throughput nucleotide sequencing

Indexed keywords

DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; TRANSCRIPTOME;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; CLONAL EVOLUTION; DNA SEQUENCE; DNMT3A GENE; EPIGENETICS; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; HUMAN; ISOCITRATE DEHYDROGENASE 1 GENE; ISOCITRATE DEHYDROGENASE 2 GENE; MUTATIONAL ANALYSIS; NEXT GENERATION SEQUENCING; ONCOGENE; PRIORITY JOURNAL; REVIEW; RNA SEQUENCE; TET2 GENE; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING;

ACUTE MYELOID LEUKEMIA; EPIGENOMICS; GENE EXPRESSION PROFILING; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING;

CLONAL EVOLUTION; EPIGENESIS, GENETIC; EXOME; GENOMICS; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; SEQUENCE ANALYSIS, DNA; TRANSCRIPTOME;

EID: 84898045456     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28552     Document Type: Review

References (111)

1. Patel JP, Gonen M, Figueroa ME, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012; 366: 1079-1089.
2. Ley TJ, Mardis ER, Ding L, et al. DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature. 2008; 456: 66-72.
3. Mardis ER,. A decade's perspective on DNA sequencing technology. Nature. 2011; 470: 198-203.
4. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010; 363: 2424-2433.
5. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009; 361: 1058-1066.
6. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013; 368: 2059-2074.
7. Walter MJ, Graubert TA, Dipersio JF, Mardis ER, Wilson RK, Ley TJ,. Next-generation sequencing of cancer genomes: back to the future. Per Med. 2009; 6: 653-653.
8. Rao AV, Smith BD,. Are results of targeted gene sequencing ready to be used for clinical decision making for patients with acute myelogenous leukemia? Curr Hematol Malig Rep. 2013; 8: 149-155.
9. Graubert TA, Mardis ER,. Genomics of acute myeloid leukemia. Cancer J. 2011; 17: 487-491.
10. Link DC,. Molecular genetics of AML. Best Pract Res Clin Haematol. 2012; 25: 409-414.
11. Welch JS, Link DC,. Genomics of AML: clinical applications of next-generation sequencing. Hematol Am Soc Hematol Educ Program. 2011;2011: 30-35.
12. Merker JD, Valouev A, Gotlib J,. Next-generation sequencing in hematologic malignancies: what will be the dividends? Ther Adv Hematol. 2012; 3: 333-339.
13. Braggio E, Egan JB, Fonseca R, Stewart AK,. Lessons from next-generation sequencing analysis in hematological malignancies [serial online]. Blood Cancer J. 2013; 3: e127.
14. Shyr D, Liu Q,. Next generation sequencing in cancer research and clinical application [serial online]. Biol Proced Online. 2013; 15: 4.
15. Maher CA, Palanisamy N, Brenner JC, et al. Chimeric transcript discovery by paired-end transcriptome sequencing. Proc Natl Acad Sci U S A. 2009; 106: 12353-12358.
16. Sulonen AM, Ellonen P, Almusa H, et al. Comparison of solution-based exome capture methods for next generation sequencing [serial online]. Genome Biol. 2011; 12: R94.
17. Clark MJ, Chen R, Lam HY, et al. Performance comparison of exome DNA sequencing technologies. Nat Biotechnol. 2011; 29: 908-914.
18. Yan XJ, Xu J, Gu ZH, et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet. 2011; 43: 309-315.
19. Grossmann V, Tiacci E, Holmes AB, et al. Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. Blood. 2011; 118: 6153-6163.
20. Greif PA, Dufour A, Konstandin NP, et al. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood. 2012; 120: 395-403.
21. Ogawa S,. Splicing factor mutations in myelodysplasia. Int J Hematol. 2012; 96: 438-442.
22. Ozsolak F, Milos PM,. RNA sequencing: advances, challenges and opportunities. Nat Rev Genet. 2011; 12: 87-98.
23. Yang Y, Walsh CE,. Spliceosome-mediated RNA trans-splicing. Mol Ther. 2005; 12: 1006-1012.
24. Kervestin S, Jacobson A,. NMD: a multifaceted response to premature translational termination. Nat Rev Mol Cell Biol. 2012; 13: 700-712.
25. Wang Z, Gerstein M, Snyder M,. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet. 2009; 10: 57-63.
26. Greif PA, Eck SH, Konstandin NP, et al. Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia. 2011; 25: 821-827.
27. McNerney ME, Brown CD, Wang X, et al. CUX1 is a haploinsufficient tumor suppressor gene on chromosome 7 frequently inactivated in acute myeloid leukemia. Blood. 2013; 121: 975-983.
28. Wen H, Li Y, Malek SN, et al. New fusion transcripts identified in normal karyotype acute myeloid leukemia [serial online]. PLoS One. 2012; 7: e51203.
29. Masetti R, Pigazzi M, Togni M, et al. CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype. Blood. 2013; 121: 3469-3472.
30. Walter RB, Laszlo GS, Alonzo TA, et al. Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group. Am J Hematol. 2013; 88: 694-702.
31. Ramsingh G, Koboldt DC, Trissal M, et al. Complete characterization of the microRNAome in a patient with acute myeloid leukemia. Blood. 2010; 116: 5316-5326.
32. Zhi F, Cao X, Xie X, et al. Identification of circulating microRNAs as potential biomarkers for detecting acute myeloid leukemia [serial online]. PLoS One. 2013; 8: e56718.
33. Starczynowski DT, Morin R, McPherson A, et al. Genome-wide identification of human microRNAs located in leukemia-associated genomic alterations. Blood. 2011; 117: 595-607.
34. Ding L, Ley TJ, Larson DE, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature. 2012; 481: 506-510.
35. Welch JS, Ley TJ, Link DC, et al. The origin and evolution of mutations in acute myeloid leukemia. Cell. 2012; 150: 264-278.
36. Smith AE, Mohamedali AM, Kulasekararaj A, et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value. Blood. 2010; 116: 3923-3932.
37. Bacher U, Weissmann S, Kohlmann A, et al. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele. Br J Haematol. 2012; 156: 67-75.
38. Weissmann S, Alpermann T, Grossmann V, et al. Landscape of TET2 mutations in acute myeloid leukemia. Leukemia. 2012; 26: 934-942.
39. Cimmino L, Abdel-Wahab O, Levine RL, Aifantis I,. TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell. 2011; 9: 193-204.
40. Abdel-Wahab O, Patel J, Levine RL,. Clinical implications of novel mutations in epigenetic modifiers in AML. Hematol Oncol Clin North Am. 2011; 25: 1119-1133.
41. Yoshida K, Sanada M, Shiraishi Y, et al. Frequent pathway mutations of splicing machinery in myelodysplasia. Nature. 2011; 478: 64-69.
42. Papaemmanuil E, Cazzola M, Boultwood J, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011; 365: 1384-1395.
43. Malcovati L, Papaemmanuil E, Bowen DT, et al. Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/ myeloproliferative neoplasms. Blood. 2011; 118: 6239-6246.
44. Mian SA, Smith AE, Kulasekararaj AG, et al. Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome. Haematologica. 2013; 98: 1058-1066.
45. Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012; 119: 2114-2121.
46. Shih AH, Abdel-Wahab O, Patel JP, Levine RL,. The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer. 2012; 12: 599-612.
47. Stirewalt DL, Radich JP,. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3: 650-665.
48. Shivarov V, Gueorguieva R, Stoimenov A, Tiu R,. DNMT3A mutation is a poor prognosis biomarker in AML: results of a meta-analysis of 4500 AML patients. Leuk Res. 2013; 37: 1445-1450.
49. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012; 119: 5824-5831.
50. Marcucci G, Metzeler KH, Schwind S, et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol. 2012; 30: 742-750.
51. Renneville A, Boissel N, Nibourel O, et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia. 2012; 26: 1247-1254.
52. Ostronoff F, Othus M, Ho PA, et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia. 2013; 27: 238-241.
53. Gaidzik VI, Schlenk RF, Paschka P, et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood. 2013; 121: 4769-4777.
54. Metzeler KH, Becker H, Maharry K, et al. ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN favorable genetic category. Blood. 2011; 118: 6920-6929.
55. Schnittger S, Eder C, Jeromin S, et al. ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome. Leukemia. 2013; 27: 82-91.
56. Bejar R, Stevenson KE, Caughey BA, et al. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. J Clin Oncol. 2012; 30: 3376-3382.
57. Damm F, Thol F, Kosmider O, et al. SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia. 2012; 26: 1137-1140.
58. Dees ND, Zhang Q, Kandoth C, et al. MuSiC: identifying mutational significance in cancer genomes. Genome Res. 2012; 22: 1589-1598.
59. Getz G, Hofling H, Mesirov JP, et al. Comment on "The consensus coding sequences of human breast and colorectal cancers" [serial online]. Science. 2007; 317: 1500.
60. Wendl MC, Wallis JW, Lin L, et al. PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics. 2011; 27: 1595-1602.
61. Ciriello G, Cerami E, Sander C, Schultz N,. Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 2012; 22: 398-406.
62. Vandin F, Upfal E, Raphael BJ,. Algorithms for detecting significantly mutated pathways in cancer. J Comput Biol. 2011; 18: 507-522.
63. Vaske CJ, Benz SC, Sanborn JZ, et al. Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM [serial online]. Bioinformatics. 2010; 26: i237-i245.
64. Forbes SA, Bindal N, Bamford S, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 2011; 39 (Database issue): D945-D950, 2011.
65. UniProt Consortium. Update on activities at the Universal Protein Resource (UniProt) in 2013. Nucleic Acids Res. 2013; 41 (Database issue): D43-D47.
66. Siepel A, Bejerano G, Pedersen JS, et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res. 2005; 15: 1034-1050.
67. Kumar P, Henikoff S, Ng PC,. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc. 2009; 4: 1073-1081.
68. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012; 2: 401-404.
69. Damm F, Kosmider O, Gelsi-Boyer V, et al. Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. Blood. 2012; 119: 3211-3218.
70. Rossi D, Bruscaggin A, Spina V, et al. Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. Blood. 2011; 118: 6904-6908.
71. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, et al. Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing [serial online]. Blood. 2012; 120: e83-e92.
72. Dawson MA, Kouzarides T,. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150: 12-27.
73. Graubert T, Walter MJ,. Genetics of myelodysplastic syndromes: new insights. Hematology Am Soc Hematol Educ Program. 2011;2011: 543-549.
74. Fathi AT, Abdel-Wahab O,. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy [serial online]. Adv Hematol 2012: 469592, 2012.
75. Ward PS, Patel J, Wise DR, et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell. 2010; 17: 225-234.
76. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell. 2010; 18: 553-567.
77. Hatzimichael E, Crook T,. Cancer epigenetics: new therapies and new challenges [serial online]. J Drug Deliv 2013: 529312, 2013.
78. Gronbaek K, Muller-Tidow C, Perini G, et al. A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica. 2012; 97: 1380-1388.
79. Jelinek J, Liang S, Lu Y, et al. Conserved DNA methylation patterns in healthy blood cells and extensive changes in leukemia measured by a new quantitative technique. Epigenetics. 2012; 7: 1368-1378.
80. Meissner A, Mikkelsen TS, Gu H, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature. 2008; 454: 766-770.
81. Down TA, Rakyan VK, Turner DJ, et al. A Bayesian deconvolution strategy for immunoprecipitation-based DNA methylome analysis. Nat Biotechnol. 2008; 26: 779-785.
82. Yan P, Frankhouser D, Murphy M, et al. Genome-wide methylation profiling in decitabine-treated patients with acute myeloid leukemia. Blood. 2012; 120: 2466-2474.
83. Saied MH, Marzec J, Khalid S, et al. Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats [serial online]. PLoS One. 2012; 7: e33213.
84. Challen GA, Berg JS, Goodell MA,. Loss of de novo DNA methylation causes expansion of the mouse hematopoietic stem cell pool. Blood. 2010; 116: 364-364.
85. Akalin A, Garrett-Bakelman FE, Kormaksson M, et al. Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia [serial online]. PLoS Genet. 2012; 8: e1002781.
86. Abdel-Wahab O, Adli M, LaFave LM, et al. ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell. 2012; 22: 180-193.
87. Saeed S, Logie C, Francoijs KJ, et al. Chromatin accessibility, p300, and histone acetylation define PML-RARalpha and AML1-ETO binding sites in acute myeloid leukemia. Blood. 2012; 120: 3058-3068.
88. Graubert TA, Shen D, Ding L, et al. Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes. Nat Genet. 2012; 44: 53-57.
89. Makishima H, Visconte V, Sakaguchi H, et al. Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood. 2012; 119: 3203-3210.
90. Przychodzen B, Jerez A, Guinta K, et al. Patterns of missplicing due to somatic U2AF1 mutations in myeloid neoplasms. Blood. 2013; 122: 999-1006.
91. Visconte V, Rogers HJ, Singh J, et al. SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. Blood. 2012; 120: 3173-3186.
92. Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med. 2012; 366: 1090-1098.
93. Walter MJ, Shen D, Shao J, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013; 27: 1275-1282.
94. Jan M, Snyder TM, Corces-Zimmerman MR, et al. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia [serial online]. Sci Transl Med. 2012; 4: 149ra18.
95. Landau DA, Carter SL, Stojanov P, et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell. 2013; 152: 714-726.
96. Conte N, Varela I, Grove C, et al. Detailed molecular characterisation of acute myeloid leukaemia with a normal karyotype using targeted DNA capture. Leukemia. 2013; 27: 1820-1825.
97. Beekman R, Valkhof MG, Sanders MA, et al. Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia. Blood. 2012; 119: 5071-5077.
98. Ding L, Raphael BJ, Chen F, Wendl MC,. Advances for studying clonal evolution in cancer. Cancer Lett. 2013; 340: 212-219.
99. Fisher R, Pusztai L, Swanton C,. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer. 2013; 108: 479-485.
100. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C,. Intratumor heterogeneity: seeing the wood for the trees [serial online]. Sci Transl Med. 2012; 4: 127ps10.
101. Abdel-Wahab O,. Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice. Hematology. 2012; 17 (suppl 1): S39-S42.
102. Tyner JW, Erickson H, Deininger MW, et al. High-throughput sequencing screen reveals novel, transforming RAS mutations in myeloid leukemia patients. Blood. 2009; 113: 1749-1755.
103. Duncavage EJ, Abel HJ, Szankasi P, Kelley TW, Pfeifer JD,. Targeted next generation sequencing of clinically significant gene mutations and translocations in leukemia. Mod Pathol. 2012; 25: 795-804.
104. Thol F, Kolking B, Damm F, et al. Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012; 51: 689-695.
105. Grossmann V, Schnittger S, Schindela S, et al. Strategy for robust detection of insertions, deletions, and point mutations in CEBPA, a GC-rich content gene, using 454 next-generation deep-sequencing technology. J Mol Diagn. 2011; 13: 129-136.
106. Rinke J, Schafer V, Schmidt M, et al. Genotyping of 25 leukemia-associated genes in a single work flow by next-generation sequencing technology with low amounts of input template DNA. Clin Chem. 2013; 59: 1238-1250.
107. Spencer DH, Abel HJ, Lockwood CM, et al. Detection of FLT3 internal tandem duplication in targeted, short-read-length, next-generation sequencing data. J Mol Diagn. 2013; 15: 81-93.
108. Wang W, Wei Z, Lam TW, Wang J,. Next generation sequencing has lower sequence coverage and poorer SNP-detection capability in the regulatory regions [serial online]. Sci Rep. 2011; 1: 55.
109. Link DC, Schuettpelz LG, Shen D, et al. Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML. JAMA. 2011; 305: 1568-1576.
110. Welch JS, Westervelt P, Ding L, et al. Use of whole-genome sequencing to diagnose a cryptic fusion oncogene. JAMA. 2011; 305: 1577-1584.
111. Griffith M, Griffith OL, Coffman AC, Weible JV, McMichael JF, Spies NC, Koval J, Das I, Callaway MB, Eldred JM, Miller CA, Subramanian J, Govindan R, Kumar RD, Bose R, Ding L, Walker JR, Larson DE, Dooling DJ, Smith SM, Ley TJ, Mardis ER, Wilson RK,. DGIdb: mining the druggable genome. Nat Methods. 2013 Dec;10(12):1209-1210. doi: 10.1038/nmeth.2689. Epub 2013 Oct 13.